SD-101

Dynavax Initiates Phase 1/2 Study of TLR-9 Agonist Immunotherapy in B-Cell Lymphoma
Yahoo
Mon, 10/13/14 - 07:26 am
Dynavax
TLR-9
immuno-oncology
B-cell lymphoma
SD-101
What Does The FDA's Breakthrough Designation Mean For Investors?
Seeking Alpha
Mon, 08/26/13 - 01:28 pm
FDA
breakthrough therapies
AbbVie
Alexion
Ariad Pharmaceuticals
Biomarin
Bristol-Myers Squibb
SynaGeva BioPharma
GSK
JNJ
Merck
Novartis
Pharmacyclics
Pfizer
Vertex Pharmaceuticals
daratumumab
ibrutinib
Kalydeco
lambrolizumab
palbociclib
LDK378
SD-101
obinutuzumab
serelaxin
asfotase alfa
bimagrumab
drisapersen
sebelipase alfa